IDXX
Healthcare · Diagnostics & Research
Performance
IDXX (IDXX) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
IDXX (IDXX) operates in the Diagnostics & Research space within the Healthcare sector. With a market cap of $45.2B, it qualifies as a mid-cap company. The company is growing revenue strongly while maintaining healthy profitability — a combination that investors typically reward with a premium valuation.
- Forward P/E (34.7×) is lower than trailing P/E (42.2×) — analysts expect earnings to improve
- Revenue growth of 14% YoY shows solid business momentum
- Exceptional profit margin of 24.6% — the business retains a large share of each dollar earned
- ROE of 72.9% shows management efficiently converts equity into profit
- High P/E of 42.2× implies high expectations already priced in — leaves little room for disappointment
- High debt-to-equity of 71.04× increases financial risk, especially with elevated interest rates
- No dividend history — total return depends entirely on price appreciation
- High beta of 1.54 — this stock is significantly more volatile than the broader market
Verdict
Hold
Mixed signals — strengths and risks roughly balance. Wait for a clearer catalyst.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Related Articles
Revenue & Results
Dividends
This stock does not pay dividends.
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Earnings
Next Earnings
Aug 3, 2026
48
days
EPS (TTM)
$13.57
P/E (TTM)
42.2
Fwd P/E
34.7
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Key Statistics
Valuation
Trading
Dividends
Profitability
Balance Sheet
Fair Value Estimates
Current price: $573.18
Graham Number
√(22.5 × EPS × Book Value)
$77.43
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
N/A
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
6/10
75% score
Pays dividends
No dividend history found
Dividend consistency (5Y+)
Uninterrupted dividend payments for at least 5 years
ROE above 10%
72.9%Return on equity — measures how efficiently capital is used
Positive profit margin
24.6%Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
+14.3%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
+17.2%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
71.04×Low financial leverage reduces risk of distress
Current ratio above 1
1.12×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$333M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
Stock must distribute income to shareholders
Related Assets
Healthcare
About IDXX
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Sector
Healthcare
Industry
Diagnostics & Research
Location
Westbrook, United States
Employees
11,000